Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease

Nephrology Dialysis Transplantation

Volumn 29, Issue 1, 2014, Pages 119-127

  Idorn, Thomas ^a   Knop, Filip K ^a   Jørgensen, Morten ^a   Holst, Jens J ^a   Hornum, Mads ^a   Feldt Rasmussen, Bo ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

end stage renal disease (ESRD); glucagon; glucagon like peptide 1 (GLP 1); glucose dependent insulinotropic polypeptide (GIP); incretin hormones; meal test

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; PANCREAS HORMONE; PARACETAMOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; END STAGE RENAL DISEASE; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; STOMACH EMPTYING;

END-STAGE RENAL DISEASE (ESRD); GLUCAGON; GLUCAGON-LIKE PEPTIDE-1 (GLP-1); GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP); INCRETIN HORMONES; MEAL TEST;

ADULT; BLOOD GLUCOSE; FEMALE; GASTRIC EMPTYING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PANCREATIC HORMONES; POSTPRANDIAL PERIOD;

EID: 84892758781     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft353     Document Type: Article

References (38)

1. Alvestrand A, Mujagic M, Wajngot A et al. Glucose intolerance in uraemic patients: the relative contributions of impaired beta-cell function and insulin resistance. Clin Nephrol 1989; 31: 175-183
2. Bilbrey GL, Faloona GR, White MG et al. Hyperglucagonemia of renal failure. J Clin Invest 1974; 53: 841-847
3. DeFronzo RA. Pathogenesis of glucose intolerance in uraemia. Metabolism 1978; 27: 1866-1880
4. Eldin WS, Ragheb A, Klassen J et al. Evidence for increased risk of prediabetes in the uraemic patient. Nephron Clin Pract 2008; 108: c47-c55
5. Idorn T, Knop FK, Jorgensen M et al. Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. Kidney Int 2013; 83: 915-923
6. Vella A, Camilleri M, Rizza RA. The gastrointestinal tract and glucose tolerance. Curr Opin Clin Nutr Metab Care 2004; 7: 479-484
7. Carr RD, Larsen MO, Winzell MS et al. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab 2008; 295: E779-E784
8. Carrel G, Egli L, Tran C et al. Contributions of fat and protein to the incretin effect of a mixed meal. Am J Clin Nutr 2011; 94: 997-1003
9. Deacon CF, Ahren B. Physiology of incretins in health and disease. Rev Diabet Stud 2011; 8: 293-306
10. Herrmann C, Goke R, Richter G et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117-126
11. Hare KJ, Vilsboll T, Asmar M et al. The glucagonostatic and insu-linotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010; 59: 1765-1770
12. Deacon CF, Plamboeck A, Rosenkilde MM et al. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. Am J Physiol Endocrinol Metab 2006; 291: E468-E475
13. Nauck MA, Bartels E, Orskov C et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypep-tide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-917
14. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498
15. Henkel E, Menschikowski M, Koehler C et al. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism 2005; 54: 1168-1173
16. Muller WA, Faloona GR, guilar-Parada E et al. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970; 283: 109-115
17. Shah P, Basu A, Basu R et al. Impact of lack of suppression of glu-cagon on glucose tolerance in humans. Am J Physiol 1999; 277: E283-E290
18. Rijkelijkhuizen JM, McQuarrie K, Girman CJ et al. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses. Metabolism 2010; 59: 502-511
19. Alberti KG, Zimmet PZ. Definition, diagnosis classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553
20. Miceli JN, Aravind MK, Cohen SN et al. Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography. Clin Chem 1979; 25: 1002-1004
21. Lindgren O, Carr RD, Deacon CF et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 2011; 96: 2519-2524
22. Knop FK, Vilsboll T, Madsbad S et al. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007; 50: 797-805
23. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
24. Wolever TM, Chiasson JL, Csima A et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75g oral glucose. Diabetes Care 1998; 21: 336-340
25. Ascaso JF, Pardo S, Real JT et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26: 3320-3325
26. Miyamoto T, Rashid QA, Yamamoto T et al. Postprandial metabolic response to a fat-and carbohydrate-rich meal in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26: 2231-2237
27. Sherwin RS, Bastl C, Finkelstein FO et al. Influence of uraemia and hemodialysis on the turnover and metabolic effects of gluca-gon. J Clin Invest 1976; 57: 722-731
28. Hansen KB, Vilsboll T, Bagger JI et al. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. J Clin Endocrinol Metab 2011; 96: 447-453
29. Rocha DM, Faloona GR, Unger RH. Glucagon-stimulating activity of 20 amino acids in dogs. J Clin Invest 1972; 51: 2346-2351
30. Calbet JA, MacLean DA. Plasma glucagon and insulin responses depend on the rate of appearance of amino acids after ingestion of different protein solutions in humans. J Nutr 2002; 132: 2174-2182
31. Lund A, Vilsboll T, Bagger JI et al. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 2011; 300: E1038-E1046
32. Heading RC, Nimmo J, Prescott LF et al. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol 1973; 47: 415-421
33. Strid H, Simren M, Stotzer PO et al. Delay in gastric emptying in patients with chronic renal failure. Scand J Gastroenterol 2004; 39: 516-520
34. Wright RA, Clemente R, Wathen R. Gastric emptying in patients with chronic renal failure receiving hemodialysis. Arch Intern Med 1984; 144: 495-496
35. Wettergren A, Schjoldager B, Mortensen PE et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673
36. Miholic J, Orskov C, Holst JJ et al. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 1991; 36: 1361-1370
37. Vilsboll T, Toft-Nielsen MB, Krarup T et al. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 2000; 23: 807-812
38. Porte D, Jr. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes 1991; 40: 166-180